Tolevamer - Sanofi
Alternative Names: Exodif; GT160-246; GT267-004; Tolevamer sodium; Tolevamer toxin binder; Tolevamer-potassium-sodium; Toxin binder - SanofiLatest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Antidiarrhoeals; Polymers; Small molecules
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 15 Jul 2008 Discontinued - Phase-III for Clostridium difficile infections in Europe (PO)
- 15 Jul 2008 Discontinued - Phase-III for Clostridium difficile infections in Australia (PO)